Sagimet CLO granted 100,000 stock options
Sagimet Biosciences Inc. reported that Chief Legal & Admin.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sagimet Biosciences Inc. reported that Chief Legal & Admin. Officer Elizabeth Rozek received a grant of stock options as part of her compensation. She was awarded 100,000 stock options, each giving the right to buy one share of Series A common stock at an exercise price of $7.27 per share. These options expire on May 27, 2036. According to the terms, the shares underlying this option will vest in 48 equal monthly installments beginning after May 28, 2026, contingent on her continued service, and her reported derivative holdings after this grant total 100,000 options.
Insider Trade Summary
Grant/Award: 100,000 shares
Grant/Award
1 txn
Insider
Rozek Elizabeth
Role
Chief Legal & Admin. Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 100,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 100,000 contracts (Direct)
Footnotes (1)
- F1. The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Stock options granted: 100,000 options
Exercise price: $7.27 per share
Expiration date: May 27, 2036
+3 more
6 metrics
Stock options granted
100,000 options
Grant to Chief Legal & Admin. Officer on May 28, 2026
Exercise price
$7.27 per share
Exercise price of granted stock options
Expiration date
May 27, 2036
Option term end date
Underlying shares
100,000 shares
Series A common stock underlying options
Vesting schedule
48 monthly installments
Vesting begins after May 28, 2026, subject to continued service
Derivative holdings after grant
100,000 options
Total derivative securities following transaction
Key Terms
Stock Option (Right to Buy), Series A Common Stock, exercise price, vesting
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Series A Common Stock financial
"underlying_security_title: Series A Common Stock"
Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.
exercise price financial
"conversion_or_exercise_price: 7.2700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Sagimet Biosciences (SGMT) report for Elizabeth Rozek?
Sagimet Biosciences reported that Chief Legal & Admin. Officer Elizabeth Rozek received a grant of 100,000 stock options. These options are a compensation award, not an open-market purchase or sale, and give her the right to buy Series A common stock at a fixed price.
What are the key terms of Elizabeth Rozek’s new stock options at Sagimet Biosciences (SGMT)?
The grant covers 100,000 stock options with an exercise price of $7.27 per share and an expiration date of May 27, 2036. Each option corresponds to one share of Series A common stock under the company’s equity compensation arrangements.
How do the Sagimet Biosciences (SGMT) options granted to Elizabeth Rozek vest?
The shares underlying the 100,000 options vest over 48 equal monthly installments after May 28, 2026. Vesting is conditioned on Elizabeth Rozek’s continued service with Sagimet Biosciences on each applicable monthly vesting date throughout the four-year period.
Did the Sagimet Biosciences (SGMT) Form 4 show any stock sales by Elizabeth Rozek?
The Form 4 shows only a grant of stock options to Elizabeth Rozek and no sales or purchases of common stock. The transaction is coded as an acquisition related to a grant or award, reflecting equity-based compensation rather than an open-market trade.
What is Elizabeth Rozek’s derivative position after this Sagimet Biosciences (SGMT) option grant?
Following the reported transaction, Elizabeth Rozek holds 100,000 derivative securities in the form of stock options. These options relate to Series A common stock, are held directly, and reflect her position as reported immediately after the compensation grant transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
